Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$29.37

-0.97 (-3.20%)

18:04
11/30/16
11/30
18:04
11/30/16
18:04

Blueprint Medicines reports 'promising' proof-of-concept data from BLU-285 trial

Blueprint Medicines announced data from its ongoing Phase 1 clinical trial evaluating BLU-285, an investigational medicine for the treatment of patients with advanced gastrointestinal stromal tumors. These data provide proof-of-concept for BLU-285, a potent, highly selective inhibitor of D842V mutant PDGFRalpha and Exon 17 mutant KIT. The data will be presented on Thursday, December 1, 2016 at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. "The clinical activity observed to date in the dose escalation portion of this Phase 1 study is promising," said Michael Heinrich, M.D., Oregon Health & Science University, an investigator for the clinical trial. "Advanced GIST is a devastating illness, marked by rapid disease progression. Seeing tumor shrinkage in 14 out of 15 PDGFRalpha-driven GIST patients at this point in the study is notable. I am also excited to see tumor shrinkage in four out of the six KIT-driven GIST patients treated at the higher dose levels, indicating the potential for increased clinical activity as we continue to dose-escalate. Given these encouraging early data for this investigational medicine, I believe BLU-285 could be transformative for patients with advanced GIST." BLU-285 is currently being evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with unresectable PDGFRalpha-driven GIST and patients with treatment-resistant KIT-driven GIST. As of the data cutoff date of November 1, 2016, 36 patients had been treated in the dose escalation portion of the Phase 1 clinical trial at seven dose levels, including 18 patients with PDGFRalpha-driven GIST and 18 patients with KIT-driven GIST. The median age was 61, and the median number of prior tyrosine-kinase inhibitor regimens was 3.5. As of the data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses. The majority of adverse events (AEs) reported by investigators were Grade 1 or 2. Across all grades, AEs reported by investigators most commonly included nausea, vomiting, peripheral edema, fatigue and constipation. Investigators reported treatment-related Grade 3 AEs in three patients: nausea and vomiting; anemia and intratumoral hemorrhage; and hypophosphatemia. No dose-limiting toxicities or drug-related Grade 4 or 5 AEs were reported, and no patients discontinued BLU-285 due to treatment-related adverse events. A maximum tolerated dose has not been reached, and enrollment in the dose escalation portion of the Phase 1 clinical trial is ongoing. Based on the favorable safety profile and encouraging clinical activity observed to date in the Phase 1 clinical trial for BLU-285 for the treatment of advanced GIST, Blueprint Medicines will continue to enroll patients in the dose escalation portion of this clinical trial until a MTD or a lower recommended dose for further clinical evaluation has been established. Enrollment in the expansion cohorts for this Phase 1 clinical trial is expected to begin in the first half of 2017. Blueprint Medicines plans to enroll approximately 35 patients with advanced GIST in the expansion cohorts. We also plan to accelerate our evaluation of expanded development options for BLU-285 in GIST, including opportunities to move to earlier lines of therapy and possible combinations.

  • 01

    Dec

  • 03

    Dec

  • 05

    Dec

BPMC Blueprint Medicines
$29.37

-0.97 (-3.20%)

05/27/16
RAJA
05/27/16
INITIATION
Target $23
RAJA
Outperform
Blueprint Medicines initiated with an Outperform at Raymond James
Raymond James analyst Chris Raymond initiated Blueprint Medicines with an Outperform rating and $23 price target. The analyst thinks Blueprint's unique kinase inhibitor discovery platform is well-positioned to generate novel compounds for years to come. Coupling this with a clinical stage pipeline that remains wholly-owned, key proof-of-concept data for two products,BLU-285 and BLU-554, in three different indications by year end 2015, and a valuation offering favorable risk/reward.
08/05/16
ADAM
08/05/16
INITIATION
Target $26
ADAM
Buy
Blueprint Medicines initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Blueprint Medicines with a Buy and $26 price target.
11/11/16
ADAM
11/11/16
NO CHANGE
Target $35
ADAM
Buy
Blueprint Medicines price target raised to $35 from $26 at Canaccord
Canaccord analyst Arlinda Lee raised her target on Blueprint Medicines to $35 from $26 following company updates on its pipeline of novel, rationally designed, target kinase inhibitors. The analyst increased her probability of success for the company's three programs to 25% from 20% and maintained her Buy rating on Blueprint Medicines shares.
11/29/16
WEDB
11/29/16
NO CHANGE
WEDB
Blueprint Medicines data 'highly encouraging,' says Wedbush
Wedbush analyst David Nierengarten says that Phase I data on Blueprint's BLU-554 for advanced HCC was "highly encouraging." The analyst says that the drug performed well compared with approved HCC therapies. Specifically, he believes that the 10% overall response rate and the fact that four out of ten patients showed radiographic tumor reductions are "promising" signs. The analyst reiterates a $41 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

MLNX

Mellanox

$64.30

-0.45 (-0.69%)

17:12
01/17/18
01/17
17:12
01/17/18
17:12
Hot Stocks
Starboard to nominate nine directors for election at Mellanox »

Starboard Value, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

APHB

AmpliPhi

$1.12

0.03 (2.75%)

17:11
01/17/18
01/17
17:11
01/17/18
17:11
Syndicate
AmpliPhi requests withdrawal of registration statement »

AmpliPhi confirms that no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$146.98

0.12 (0.08%)

17:05
01/17/18
01/17
17:05
01/17/18
17:05
Hot Stocks
Johnson & Johnson issues statement on ZYTIGA Inter Partes reviews »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

EVEP

EV Energy

$0.89

0.015 (1.71%)

17:03
01/17/18
01/17
17:03
01/17/18
17:03
Hot Stocks
EV Energy announces extension of grace period to meet NASDAQ requirement »

EV Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$10.05

0.1 (1.01%)

17:02
01/17/18
01/17
17:02
01/17/18
17:02
Hot Stocks
Hudbay Minerals sees FY18 CapEx $245M »

Hudbay Minerals released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFE

Safeguard Scientifics

$10.85

-0.15 (-1.36%)

17:02
01/17/18
01/17
17:02
01/17/18
17:02
Hot Stocks
Safeguard Scientifics to implement changes in business strategy and operations »

Safeguard Scientifics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$97.28

1.42 (1.48%)

, SSTI

ShotSpotter

$16.10

0.06 (0.37%)

16:55
01/17/18
01/17
16:55
01/17/18
16:55
Hot Stocks
Motorola Solutions reports 9.8% passive stake in ShotSpotter »

In a regulatory filing,…

MSI

Motorola Solutions

$97.28

1.42 (1.48%)

SSTI

ShotSpotter

$16.10

0.06 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

ERIE

Erie Indemnity

$117.23

1.44 (1.24%)

16:52
01/17/18
01/17
16:52
01/17/18
16:52
Hot Stocks
Erie Indemnity sees $20M in tax expense as a result of new tax law »

Erie Indemnity expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.10

2.91 (1.65%)

16:52
01/17/18
01/17
16:52
01/17/18
16:52
Periodicals
Apple to issue $2,500 restricted stock bonuses to workers, Bloomberg says »

Apple informed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SLM

Sallie Mae

$11.49

0.02 (0.17%)

16:51
01/17/18
01/17
16:51
01/17/18
16:51
Earnings
Sallie Mae reports Q4 core EPS 19c, consensus 19c »

Reports Q4 GAAP net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

16:45
01/17/18
01/17
16:45
01/17/18
16:45
General news
Treasury TIC flows: foreign accounts bought $33.8 B in total U.S. assets »

Treasury TIC flows:…

VZ

Verizon

$51.72

0.06 (0.12%)

16:43
01/17/18
01/17
16:43
01/17/18
16:43
Hot Stocks
Verizon to record cumulative adjustment to retained earnings during 1Q18 »

Verizon said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VZ

Verizon

$51.72

0.06 (0.12%)

16:42
01/17/18
01/17
16:42
01/17/18
16:42
Hot Stocks
Verizon sees $4.10 impact to FY17 EPS after tax reform »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BELFA

Bel Fuse

, BELFB

Bel Fuse

$24.70

0.25 (1.02%)

16:39
01/17/18
01/17
16:39
01/17/18
16:39
Earnings
Bel Fuse anticipates Q4 revenue $120M, 1 estimate $124M »

The company's…

BELFA

Bel Fuse

BELFB

Bel Fuse

$24.70

0.25 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:37
01/17/18
01/17
16:37
01/17/18
16:37
General news
API crude inventories for week of January 12 »

API reports that crude…

SLM

Sallie Mae

$11.49

0.02 (0.17%)

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Earnings
Sallie Mae sees initial FY18 EPS 97c-$1.01, consensus $1.04 »

Sees FY18 private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Hot Stocks
Antero Midstream GP provides distribution guidance for 2018 through 2022 »

Antero Midstream GP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Hot Stocks
Antero Resources sees FY18 CapEx $1.45B »

Antero's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:35
01/17/18
01/17
16:35
01/17/18
16:35
Hot Stocks
Antero Resources sees Q4 net daily gas equivalent production 2,347 MMcfe/d »

Preliminary Fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

HBHC

Hancock Holding

$54.45

0.9 (1.68%)

16:35
01/17/18
01/17
16:35
01/17/18
16:35
Earnings
Hancock Holding reports Q4 EPS with items 64c, consensus 83c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:34
01/17/18
01/17
16:34
01/17/18
16:34
Hot Stocks
Antero Resources sees net daily production approximately 2.7 Bcfe/d in 2018 »

2018 Guidance and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

16:33
01/17/18
01/17
16:33
01/17/18
16:33
Hot Stocks
Antero Midstream Partners provides 2018 and long-term target guidance »

Antero Midstream provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

SBOW

SilverBow Resources

$31.48

0.52 (1.68%)

16:32
01/17/18
01/17
16:32
01/17/18
16:32
Hot Stocks
SilverBow Resources sees 2018 capital program of $245M-$265M »

SilverBow Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

RDN

Radian Group

$22.26

0.13 (0.59%)

16:31
01/17/18
01/17
16:31
01/17/18
16:31
Hot Stocks
Radian Group updates on capital actions »

Radian Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.02

0.48 (0.90%)

16:30
01/17/18
01/17
16:30
01/17/18
16:30
Initiation
Hess Corp. initiated  »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.